Given that the low mutation frequency of RB1 (4.83%) (Figure S2B) is neither conducive to subsequent experimental validation (Hep3B is the only RB1-mutated liver cancer cell line recorded in CCLE) nor favorable for its potential clinical application, we selected the TP53-PLK1 for subsequent validation. Here, TP53 is linked to liver cancer.